Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025

Rhea-AI Summary

Exagen (Nasdaq: XGN) will release financial results for the quarter ended September 30, 2025 before the market opens on Tuesday, November 4, 2025. A conference call and webcast to review results will be held at 8:30 a.m. ET / 5:30 a.m. PT with John Aballi, President and CEO, and Jeff Black, CFO.

Conference call details: U.S. dial-in 201-389-0918; international dial-in 877-407-0890; webcast available at investors.exagen.com. A telephone replay is available through Tuesday, November 18, 2025 (U.S. replay 201-612-7415; international replay 877-660-6853; replay passcode 13756599). A recording of the webcast will be posted about one hour after the call at investors.exagen.com.

CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday, November 4, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT).

Conference Call & Webcast:

• U.S. dial-in: 201-389-0918
• International dial-in: 877-407-0890
• Webcast: Available via the Exagen investor relations website at investors.exagen.com
  
  

Replay: A telephone replay will be available until Tuesday, November 18, 2025:

• U.S. replay: 201-612-7415
• International replay: 877-660-6853
• Replay passcode: 13756599
• Webcast: A recoding of the webcast will be available one hour after the call concludes via the Exagen investor relations website at investors.exagen.com
  
  

About Exagen Inc.

Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE^® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.

For more information, visit Exagen.com or follow Exagen on LinkedIn.

Contact:

Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525

FAQ

When will Exagen (XGN) report third quarter 2025 results?

Exagen will release results for the quarter ended September 30, 2025 before the market opens on November 4, 2025.

What time is the Exagen (XGN) earnings call on November 4, 2025?

The conference call is scheduled for 8:30 a.m. ET / 5:30 a.m. PT on November 4, 2025.

Who will host Exagen's (XGN) November 4, 2025 earnings call?

The call will be hosted by John Aballi, President and CEO, and Jeff Black, CFO.

How can investors join the Exagen (XGN) webcast for the November 4, 2025 call?

The webcast will be available at investors.exagen.com.

What are the dial-in numbers for Exagen's (XGN) November 4, 2025 conference call?

U.S. dial-in is 201-389-0918; international dial-in is 877-407-0890.

How can I access the replay of Exagen's (XGN) November 4, 2025 call and until when?

A telephone replay is available until November 18, 2025: U.S. replay 201-612-7415, international replay 877-660-6853, replay passcode 13756599; a webcast recording posts about one hour after the call at investors.exagen.com.